European Commission approves toripalimab for NPC and advanced ESCC, first drug for NPC, first-line treatment for advanced ESCC.

The European Commission has approved toripalimab (Loqtorzi®), developed by Shanghai Junshi Biosciences, for two cancer treatments: recurrent, inoperable nasopharyngeal carcinoma (NPC) and unresectable advanced esophageal squamous cell carcinoma (ESCC). It is the first drug in Europe for NPC and the first-line treatment for advanced ESCC, regardless of PD-L1 status. The approval follows positive results from Phase III clinical trials, showing improved survival rates.

September 25, 2024
5 Articles